agency: The Zero-Knowledge R&D Core

Unlocking Institutional Memory and AI-Driven Discovery without IP Leakage

Date: December 2025 Prepared For: CSOs, CIOs, and R&D Directors in Life Sciences

1. Executive Summary

In Life Sciences, data is the product. A single file containing a novel small molecule structure or a toxicology assay represents billions in potential revenue—or catastrophic loss if leaked.

R&D organizations face a critical deadlock in 2025:

1. The AI Imperative: Scientists desperately need Generative AI to synthesize literature, draft INDs, and analyze assays.
2. The "Shadow AI" Risk: Frustrated by IT blocks, over 98% of researchers admit to using unsanctioned public AI tools (ChatGPT, Claude) to accelerate work, effectively exfiltrating trade secrets to third-party model trainers.
3. The "Dark Data" Crisis: While structured data sits in ELNs (Benchling/Dotmatics), the *context*—failed hypotheses, meeting notes, and CRO reports—remains trapped in unsearchable PDFs. This "Institutional Amnesia" costs the industry $28 billion annually in irreproducible research.

Agency resolves this tension. By deploying a Zero-Knowledge Knowledge Base (ZKKB) that runs AI locally or inside client-controlled Trusted Execution Environments (TEEs), Agency allows R&D teams to index, graph, and query their entire corpus of trade secrets—without a single byte of plaintext ever leaving the firm's control.

2. The 2025 Threat Landscape

2.1 The "Shadow AI" Biohazard

The biggest risk to IP is no longer a sophisticated state-sponsored hack; it is a helpful scientist.

• The Behavior: To meet aggressive timelines, researchers paste proprietary sequences or clinical summaries into public LLMs for "quick feedback."
• The Consequence: Material Non-Public Information (MNPI) and novel IP are ingested by public model weights, effectively publishing the patent before it is filed.

2.2 The $28 Billion "Reproducibility Crisis"

The US preclinical research sector wastes ~$28B/year on irreproducible studies.

• The Cause: "Dark Data." A scientist in Cambridge starts a target validation study, unaware that a team in San Francisco failed at the same attempt three years ago. The negative result was buried in a PDF on SharePoint, invisible to the ELN.
• The Cost: Wasted reagents, lost time, and "zombie projects" that should have been killed early.

2.3 The Collaboration Gap (CROs & Partners)

Drug development is a team sport involving CROs and academic partners. Current sharing methods (Email/Box) rely on server-side encryption. The vendor holds the keys. If the vendor is subpoenaed or breached, the pipeline is exposed.

3. The Agency Solution: Sovereign Science

Agency introduces a new architecture: Sovereign AI. We bring the compute to the data, rather than sending the data to the cloud.

3.1 The "Sealed Clean Room" (TEE)

• Local-First: For early-stage discovery, Agency runs on the scientist's high-performance workstation (GPU-accelerated).
• Trusted Execution Environments: For cross-team collaboration, Agency utilizes TEEs (AWS Nitro / Azure SEV-SNP). These are "Sealed Clean Rooms" in the cloud where data is decrypted only in volatile memory, processed, and immediately re-encrypted. Even the cloud provider cannot peer inside.

3.2 Visual Architecture (C4 Model)

4. Operational Capabilities: Making Data "FAIR"

Agency makes unstructured data Findable, Accessible, Interoperable, and Reusable.

4.1 Curing Institutional Amnesia (Negative Results)

• Capability: Agency ingests legacy PDF reports, emails, and PowerPoint decks.
• Scenario: A scientist asks, *"Has anyone tested Compound X against Target Y?"*
• Result: Agency retrieves a 5-year-old "failed" report from a different therapeutic area.
• ROI: Saves $50k in reagents and 6 weeks of lab time instantly.

4.2 The "Clean Room" Literature Review

• Capability: Ingest 5,000 external patents and internal memos into a secure Agency workspace.
• Scenario: *"Identify mechanisms of action in these patents that conflict with our molecule's approach."*
• Safety: The internal molecule structure is never exposed to a public search engine or vector database.

4.3 IND Application Acceleration

• Capability: RAG-based drafting with citations.
• Scenario: *"Draft the 'Mechanism of Action' section for the IND based on these 50 assay reports."*
• Defensibility: Every sentence in the draft includes a clickable citation to the source PDF, ensuring regulatory accuracy (GxP).

5. Economic Impact & ROI

The cost of "Bad Data" far exceeds the cost of software.

Scenario: A mid-sized Biotech with 200 scientists and 10 years of legacy data.

The "One-Save" Rule: If Agency prevents one failed Phase I trial or one redundant toxicology study, it pays for the entire organization's license for a decade.

6. Security & Compliance: Beyond HIPAA

Life Sciences requires data integrity (GxP, 21 CFR Part 11) and absolute confidentiality.

6.1 Immutable Chain of Custody

Every search, view, and export is cryptographically logged in an immutable audit trail signed by the organization's keys. This creates a tamper-evident record of data handling, critical for regulatory inspections.

6.2 Encryption Specifics

• Algorithm: XChaCha20-Poly1305 (192-bit nonce).
• Benefit: Enables safe encryption on distributed devices (laptops) without a central key server, perfect for decentralized research teams.

Find about more by visiting the Security Deep-dive document.

7. Comparative Analysis: Agency vs. The Incumbents

Strategic Fit: Agency does not replace the ELN. It wraps around it, indexing the *exports* and the *human context* that the ELN misses.

8. Conclusion

For the Life Sciences industry, the choice has historically been between Utility (Risky Cloud AI) and Security (Dumb Air-gapped Silos).

Agency eliminates this compromise. By bringing the AI to the data and securing it with zero-knowledge encryption, Agency allows R&D organizations to finally unlock their "Dark Archives." It turns years of static reports into a dynamic, queryable brain, accelerating the path from Hypothesis to Therapy while ensuring the IP remains sovereign.